건강한 지원자에 있어서 타이록신 캡슐 경구투여 후의 체내 동태

Abstract

The pharmacokinetics of orally administered cefroxadine (500 mg) was studied in human. Analytical method of cefroxadine was developed and validated using HPLC with UV detector. After the validation of this method, we conducted bioavailability study by administering two Tiroxin capsules (250 mg of cefroxadine capsule) to 9 healthy volunteers (male 7, female 2) orally after overnight fasting. Blood samples were taken at 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, and 6 hrs following an oral administration of the drug and the concentrations of cefroxadine in plasma were determined. The pharmacokinetic parameters such as AUCt (the area under the plasma concentration-time curve from time zero to 6 hours), C_(max) (maximun plasma drug concentration), T_(max) (time to reach C_(max)) , K_(e), (elimination rate constant), t_(1/2) (half-life) were calculated using the 'K-BE test 2002 (BA Calc 2002) program. The calculated average pharmacokinetic parameters were as follows; AUCt (39.6 ± 8.02 μg·hr/mL), C_(max) (21.3± 4.76 μg/mL), T_(max)(1.25± 0.38 hr), K_(e), (0.621 ± 0.100 hr^(-1)), t_(1/2) (1.25 ± 0.38 hr).